Emmaus Life Sciences, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

SELECTED FINANCIAL STATEMENT ASSETS

SELECTED FINANCIAL STATEMENT ASSETS

12 Months Ended

Dec. 31, 2024

Balance Sheet Related Disclosures [Abstract]

SELECTED FINANCIAL STATEMENT ASSETS

NOTE 4—SELECTED FINANCIAL STATEMENT ASSETS

Inventories consisted of the following (in thousand):


	As of December 31
	2024			2023
Raw materials and components	$	1,147		$	1,329
Work-in-process		184			186
Finished goods		5,328			5,163
Inventory reserve		(5,024	)		(4,967	)
Total inventories, net	$	1,635		$	1,711

Prepaid expenses and other current assets consisted of the following (in thousands):


	As of December 31
	2024		2023
Prepaid insurance	$	622	$	595
Prepaid expenses		272		536
Other current assets		226		596
Total prepaid expenses and other current assets	$	1,120	$	1,727

Property and equipment consisted of the following (in thousands):


	As of December 31
	2024			2023
Equipment	$	357		$	383
Leasehold improvements		15			39
Furniture and fixtures		30			99
Total property and equipment		402			521
Less: accumulated depreciation		(356	)		(462	)
Total property and equipment, net	$	46		$	59

For the years ended December 31, 2024 and 2023, depreciation expenses were approximately $22,000 and $32,000, respectively reported in general and administrative expenses in the consolidated statements of operations.